Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2012

01.11.2012 | Original Article

Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis

verfasst von: Shushan Yan, Donghua Xu, Beicheng Sun

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent studies suggest that the combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have a synergistic effect for hepatocellular carcinoma (HCC).

Aims

The aim of this meta-analysis was to compare the effectiveness of combination of RFA and TACE with that of RFA alone in patients with HCC.

Methods

Randomized controlled trials and retrospective cohort studies comparing RFA plus TACE with RFA alone for HCC were included into this meta-analysis. Study quality was rated with a standardized scale and the strength of evidence was also rated by using the grading of recommendations assessment, development, and evaluation system (GRADE system).

Results

Meta-analyses showed that the combination of RFA and TACE was obviously associated with higher survival rates (odds ratio [OR]1-year = 2.14, 95 % confidence interval [95 % CI] 1.57–2.91, P < 0.001; OR3-year = 1.98, 95 % CI 1.28–3.07, P = 0.001; OR5-year = 2.70, 95 % CI 1.42–5.14, P = 0.003). The overall quality of evidence was judged to be low by using the GRADE system.

Conclusions

The combination of TACE with RFA can improve the overall survival rate and provides better prognosis for patients with HCC, but more randomized controlled trials using large sample size are needed to provide sufficient evidence.
Literatur
1.
Zurück zum Zitat Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–773.PubMedCrossRef Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–773.PubMedCrossRef
2.
Zurück zum Zitat Guimaraes M, Uflacker R. Locoregional therapy for hepatocellular carcinoma. Clin Liver Dis. 2011;15:395–421.PubMedCrossRef Guimaraes M, Uflacker R. Locoregional therapy for hepatocellular carcinoma. Clin Liver Dis. 2011;15:395–421.PubMedCrossRef
3.
Zurück zum Zitat Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010;52:380–388.PubMedCrossRef Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010;52:380–388.PubMedCrossRef
4.
Zurück zum Zitat Kim JW, Kim JH, Won HJ, et al. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012;81:e189–193. Kim JW, Kim JH, Won HJ, et al. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012;81:e189–193.
5.
Zurück zum Zitat Kim JH, Won HJ, Shin YM, et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18:1624–1629.PubMedCrossRef Kim JH, Won HJ, Shin YM, et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18:1624–1629.PubMedCrossRef
6.
Zurück zum Zitat Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741–749.PubMedCrossRef Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741–749.PubMedCrossRef
7.
Zurück zum Zitat Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210–1224.PubMedCrossRef Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210–1224.PubMedCrossRef
8.
Zurück zum Zitat Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.PubMedCrossRef Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.PubMedCrossRef
9.
Zurück zum Zitat Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.PubMedCrossRef Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.PubMedCrossRef
10.
Zurück zum Zitat Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedCentralPubMedCrossRef Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.PubMed
12.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.PubMedCrossRef
13.
Zurück zum Zitat Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129.CrossRef Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129.CrossRef
14.
Zurück zum Zitat Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.PubMedCrossRef Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.PubMedCrossRef
15.
Zurück zum Zitat Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905–913.PubMedCrossRef Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905–913.PubMedCrossRef
16.
Zurück zum Zitat Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669–1677.PubMedCrossRef Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669–1677.PubMedCrossRef
17.
Zurück zum Zitat Aikata H, Shirakawa H, Takaki S. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatology. 2006;44:A487.CrossRef Aikata H, Shirakawa H, Takaki S. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatology. 2006;44:A487.CrossRef
18.
Zurück zum Zitat Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–5460.PubMedCrossRef Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–5460.PubMedCrossRef
19.
Zurück zum Zitat Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology. 2005;52:1403–1407.PubMed Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology. 2005;52:1403–1407.PubMed
20.
Zurück zum Zitat Kang CB, Xu HB, Wang SL, Rui B. Treatment of large hepatoma by TACE in combination with RFA. Chin J Hepatobiliary Surg. 2007;13:828–830. Kang CB, Xu HB, Wang SL, Rui B. Treatment of large hepatoma by TACE in combination with RFA. Chin J Hepatobiliary Surg. 2007;13:828–830.
21.
Zurück zum Zitat Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation. Ai Zheng. 2005;24:827–833 [Article in Chinese].PubMed Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation. Ai Zheng. 2005;24:827–833 [Article in Chinese].PubMed
22.
Zurück zum Zitat Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther. 2008;25:787–794.PubMedCrossRef Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther. 2008;25:787–794.PubMedCrossRef
23.
Zurück zum Zitat Xu L, Li P, Chen MS, et al. Percutaneous radiofrequency ablation combined with other minimally invasive treatments for recurrent hepatocellular carcinoma after hepatectomy. Zhonghua Wai Ke Za Zhi. 2008;46:1617–1620 [Article in Chinese].PubMed Xu L, Li P, Chen MS, et al. Percutaneous radiofrequency ablation combined with other minimally invasive treatments for recurrent hepatocellular carcinoma after hepatectomy. Zhonghua Wai Ke Za Zhi. 2008;46:1617–1620 [Article in Chinese].PubMed
24.
Zurück zum Zitat Shen L, Chen MH, Yan K, et al. Clinical application of a combination therapy of percutaneous radiofrequency and transcatheter arterial chemoembolization in large hepatic tumors. Zhonghua Chao Sheng Yin Xiang Xue Za Zhi. 2004;13:577–580 [Article in Chinese]. Shen L, Chen MH, Yan K, et al. Clinical application of a combination therapy of percutaneous radiofrequency and transcatheter arterial chemoembolization in large hepatic tumors. Zhonghua Chao Sheng Yin Xiang Xue Za Zhi. 2004;13:577–580 [Article in Chinese].
25.
Zurück zum Zitat Zhang HC, Liang J. Radiofrequency ablation or transcather arterial chemoembolization for management of hepatocellular carcinoma. Zhong Guo Yi Shi Jin Xiu Za Zhi. 2007;30:67–68 [Article in Chinese]. Zhang HC, Liang J. Radiofrequency ablation or transcather arterial chemoembolization for management of hepatocellular carcinoma. Zhong Guo Yi Shi Jin Xiu Za Zhi. 2007;30:67–68 [Article in Chinese].
26.
Zurück zum Zitat Liang MH. Transcather arterial chemoembolization combined with radiofrequency ablation for the management of hepatocellular carcinoma. Zhong Guo Lao Nian Yi Xue Za Zhi. 2011;31:2862–2864 [Article in Chinese]. Liang MH. Transcather arterial chemoembolization combined with radiofrequency ablation for the management of hepatocellular carcinoma. Zhong Guo Lao Nian Yi Xue Za Zhi. 2011;31:2862–2864 [Article in Chinese].
27.
Zurück zum Zitat Luo ZG, Xiong K, Duan QW, Ren JM, Wang DW, Li C. Therapy of 3-dimension conformui technology guided radiofrequency ablation and trascatheter arterial chemoembolizatlon in primary hepatic carcinonm. Yunyang Yi Xue Yuan Xue Bao. 2008;27:22–25 [Article in Chinese]. Luo ZG, Xiong K, Duan QW, Ren JM, Wang DW, Li C. Therapy of 3-dimension conformui technology guided radiofrequency ablation and trascatheter arterial chemoembolizatlon in primary hepatic carcinonm. Yunyang Yi Xue Yuan Xue Bao. 2008;27:22–25 [Article in Chinese].
28.
Zurück zum Zitat Li ZR, Kang Z, Qian JS, et al. Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:1749–1751 [Article in Chinese].PubMed Li ZR, Kang Z, Qian JS, et al. Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:1749–1751 [Article in Chinese].PubMed
29.
Zurück zum Zitat Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009;39:231–240.PubMedCrossRef Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009;39:231–240.PubMedCrossRef
30.
Zurück zum Zitat Peng ZW, Chen MS, Liang HH, et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010;36:257–263.PubMedCrossRef Peng ZW, Chen MS, Liang HH, et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010;36:257–263.PubMedCrossRef
31.
Zurück zum Zitat Hu YQ. Radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Contemp Med. 2011;17:232–233 [Article in Chinese]. Hu YQ. Radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Contemp Med. 2011;17:232–233 [Article in Chinese].
32.
Zurück zum Zitat Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–458.PubMedCrossRef Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–458.PubMedCrossRef
33.
Zurück zum Zitat Jarnagin W, Chapman WC, Curley S, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxf). 2010;12:302–310. Jarnagin W, Chapman WC, Curley S, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxf). 2010;12:302–310.
34.
Zurück zum Zitat Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–459.PubMedCrossRef Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–459.PubMedCrossRef
35.
Zurück zum Zitat Wang N, Guan Q, Wang K, et al. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol. 2011;28:1038–1043.PubMedCrossRef Wang N, Guan Q, Wang K, et al. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol. 2011;28:1038–1043.PubMedCrossRef
36.
Zurück zum Zitat Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209–217.PubMedCrossRef Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209–217.PubMedCrossRef
Metadaten
Titel
Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis
verfasst von
Shushan Yan
Donghua Xu
Beicheng Sun
Publikationsdatum
01.11.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2212-6

Weitere Artikel der Ausgabe 11/2012

Digestive Diseases and Sciences 11/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.